Among the people receiving AstraZenece drug treatment, whether there are rare but severe blood clot cases is more common than in the general population. If so, what causes them to continue to undermine their confidence in the vaccine, France Presse said Write before accepting the new assessment. The European Medicines Agency (EMA) this week.
The European Medicines Agency (EMA) concluded that the benefits of this vaccine outweigh the risks and should continue to be used. The agency will issue an updated assessment next week.
The French Agency for Medicines (ANSM) described blood clots in people vaccinated with AstraZenecom as “very atypical”.
The agency commented: “This type of large vein thrombosis is abnormally located in the brain and is even less common in the digestive system.”
It also links it to diseases characterized by abnormally low levels of platelets in the blood, which act to form blood clots to stop or prevent bleeding.
In mid-March, the Paul Ehrlich Institute (PEI) became the first national agency to discuss the increase in these rare cases of cerebral thrombosis, mainly targeting young and middle-aged women.
Some experts mentioned so-called disseminated intravascular coagulation (DIC), in which blood clots form throughout the body.
Odile Launay, a member of the scientific agency that advises the French government, told the French government that this situation can also occur in extreme cases of sepsis, including “thrombosis and bleeding.”
EMA announced last week: “The causal relationship with the vaccine has not been confirmed, but it is possible, and further analysis is still going on.” The agency will discuss the issue again between April 6th and 9th.
Other experts are more aware of the symptoms of the British-Swedish vaccine.
The head of the Oslo National Hospital team, Pal Andre Holme, told Norwegian TV: “We need to stop speculating whether there is a connection. All these cases will be three to ten days after the AstraZeneca vaccination. Symptoms appear.”.
He added: “We did not find other triggers.”
The Norwegian Medicines Agency supports this assessment, one of its leaders Steinar Madsen (Steinar Madsen) said, “may be related to the vaccine.”
The French ANSM finally announced that there is a “smaller” risk, that is, a “very unusual type of thrombosis with similar clinical characteristics and the same time frame”.
As of March 31, EMA had identified 62 cases of cerebral venous sinus thrombosis (CVST) worldwide, of which 44 were in Europe, of which 9.2 million doses of AstraZeneca had been given, France Presse wrote.